ISSN: 0034-8376
eISSN: 2564-8896
eISSN: 2564-8896
VOLUME 68 - NUMBER 4 / July - August (Brief Communication)
Mónica León-González, Centro de HematologÃa y Medicina Interna de Puebla, ClÃnica Ruiz, Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico
Andrés León-Peña, Centro de HematologÃa y Medicina Interna de Puebla, ClÃnica Ruiz, Puebla, Pue.; Mexico
MarÃa Fernanda Vallejo-Villalobos, Universidad Popular Autónoma del Estado de Puebla; Laboratorios ClÃnicos de Puebla, ClÃnica RUIZ, Puebla, Pue., Mexico
Ana Karen Núñez-Cortés, Centro de HematologÃa y Medicina Interna de Puebla, ClÃnica Ruiz; Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Alejandro Ruiz-Argüelles, Laboratorios ClÃnicos de Puebla; Universidad de las Américas Puebla, Puebla, Mexico
Guillermo J. Ruiz-Argüelles, Centro de HematologÃa y Medicina Interna, ClÃnica Ruiz, Puebla; Faculty of Medicine, Universidad Popular Autónoma del Estado de Puebla, Puebla, Mexico
Background: Following the release of the initial presentation of filgrastim (granulocyte colony-stimulating factor), several biosimilars have been developed worldwide. Objective: To study the efficacy of a Mexican biosimilar granulocyte colony-stimulating factor in a single transplant center. Methods: In a group of 19 consecutive patients with multiple sclerosis given autografts, we employed granulocyte colony-stimulating factors to mobilize stem cells from the bone marrow to the peripheral blood, either the original granulocyte colony-stimulating factor (n = 10) or a Mexican granulocyte colony-stimulating factor biosimilar (n = 9). Results: The efficacy of both agents was similar in mobilization capacity, white blood cell count rise, stem cell collection, and kinetics of auto-engraftment. Conclusion: We conclude that both granulocyte colony-stimulating factor agents were similar in their efficacy to mobilize stem cells and usefulness in autografts.
Keywords: Biosimilar. Filgrastim. G-CSF. HSCT
Full Article in PDF
